Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

Prospectus Supplement Filed Pursuant to Rule 424(b)(5)
(To Prospectus Dated October 28, 2014) Registration No. 333-198647

https://www.sec.gov/Archives/edgar/data/1208261/000114420416115386/v445479_424b5.htm

IMMUNE PHARMACEUTICALS INC.

3,174,603 Shares of Common Stock

We are offering up to 3,174,603 shares of our common stock to institutional investors pursuant to this prospectus supplement and the accompanying prospectus and a stock purchase agreement with such investors, at a negotiated price of $0.315 per share.

In a concurrent private placement, we are selling to the purchasers of shares of our common stock offered under this prospectus supplement, warrants to purchase up to a number of shares of common stock equal to 50% of the purchasers’ subscription amounts divided by the exercise price of the warrants of $1.00 per share (collectively, the “Warrants”). The Warrants and the shares of our common stock issuable upon the exercise of the Warrants are not being registered under the Securities Act of 1933, as amended, (the “Securities Act”), are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.



Our common stock is traded on The NASDAQ Capital Market, or NASDAQ, under the symbol “IMNP”. On July 28, 2016, the last reported sale price of our common stock was $0.39 per share. The Warrants being issued in the concurrent private placement are not listed on any securities exchange and we do not expect to list the Warrants.

As of July 29, 2016, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $31.6 million, based on 63,576,143 shares of outstanding common stock, of which 5,057,528 were held by affiliates, and a per share price of $0.54 based on the closing price of our common stock on June 21, 2016. During the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement, and including this offering, we have offered securities with an aggregate market value of approximately $7.4 million pursuant to General Instruction I.B.6 on Form S-3.

Investor 100